{"protocolSection":{"identificationModule":{"nctId":"NCT04515524","orgStudyIdInfo":{"id":"VGFTe-ROP-2036"},"secondaryIdInfos":[{"id":"2020-005875-10","type":"EUDRACT_NUMBER"},{"id":"2024-513231-24-00","type":"REGISTRY","domain":"EU CT Number"}],"organization":{"fullName":"Regeneron Pharmaceuticals","class":"INDUSTRY"},"briefTitle":"Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)","officialTitle":"An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study"},"statusModule":{"statusVerifiedDate":"2025-04","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-02-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11-05","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-08-04","studyFirstSubmitQcDate":"2020-08-14","studyFirstPostDateStruct":{"date":"2020-08-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-05-09","lastUpdatePostDateStruct":{"date":"2025-05-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Regeneron Pharmaceuticals","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Primary objectives of the study are:\n\n* To evaluate binocular visual acuity at the end of this study in patients included from the VGFTe-ROP-1920 study, for treatment of Retinopathy of Prematurity (ROP).\n* To evaluate long-term safety outcomes in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.\n\nSecondary objectives of the study are:\n\n* To describe visual function in patients included from the VGFTe-ROP-1920 study, for treatment of ROP.\n* To describe overall development in patients included from the VGFTe-ROP-1920 study, for treatment of ROP."},"conditionsModule":{"conditions":["Retinopathy of Prematurity"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":100,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ROP patients from VGFTe-ROP-1920","description":"Retinopathy of prematurity (ROP) who were treated with aflibercept and/or laser photocoagulation in study VGFTe-ROP-1920.","interventionNames":["Other: Non-Interventional"]}],"interventions":[{"type":"OTHER","name":"Non-Interventional","description":"No study treatment will be administered in this study","armGroupLabels":["ROP patients from VGFTe-ROP-1920"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Binocular best-corrected visual acuity (BCVA)","timeFrame":"5 years of chronological age"},{"measure":"Proportion of Patients with Adverse Events","timeFrame":"Up to 5 years of chronological age"},{"measure":"Proportion of Patients with Serious Adverse Events","timeFrame":"Up to 5 years of chronological age"}],"secondaryOutcomes":[{"measure":"Proportion of patients developing unfavorable ocular structural outcome","description":"Unfavorable ocular structural outcome: retinal detachment, macular dragging, macular fold, retrolental opacity","timeFrame":"3 years of chronological age, 5 years of chronological age"},{"measure":"BCVA in each eye","timeFrame":"3 year of chronological age, 5 years of chronological age"},{"measure":"Refractive spherical equivalent in each eye","timeFrame":"3 years of chronological age, 5 years of chronological age"},{"measure":"Neurodevelopmental outcomes using BSID-III","description":"The Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) is a standard series of tests that will assess the development of children in 3 areas: cognition, language, and motor skills. This is a mandatory assessment to be performed at 2 years of age.","timeFrame":"2 years of chronological age"},{"measure":"Neurodevelopmental outcomes using WPPSI-IV","description":"The Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) is designed to assess development of older children and is recommended to be performed at 3, 4 and 5 years of age. The assessment at 5 years of age is mandatory. In cases where the WPSSI-IV cannot be used, the Differential Ability Scales II (DAS-II) may be used as an alternative.","timeFrame":"5 years of chronological age"},{"measure":"Neurodevelopmental outcomes using VABS-II","description":"The Vineland Adaptive Behavior Scales, Second Edition (VABS-II) Expanded Interview will be included, which includes 4 areas: Communication, Daily Living skills, Socialization and Motor Skills. The assessments at 2 years and 5 years of age are mandatory.","timeFrame":"2 years of chronological age, 5 years of chronological age"},{"measure":"Proportion of patients with recurrence of ROP","timeFrame":"3 years of chronological age, 5 years of chronological age"},{"measure":"Proportion of patients requiring treatment for ROP","timeFrame":"Through 5 years of chronological age"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patient was treated in study VGFTe-ROP-1920\n2. Age \\<13 months of chronological age\n3. Signed informed consent from parent(s)/legal guardian(s), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol\n\nExclusion Criteria:\n\n1\\. Patient has a condition preventing participation in the study, or performance of study procedures\n\nNOTE: Other Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"11 Months","maximumAge":"5 Years","stdAges":["CHILD"],"studyPopulation":"All patients who were treated in the VGFTe-ROP-1920 study are eligible for enrollment into this follow-up study.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trial Management","affiliation":"Regeneron Pharmaceuticals","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"UCSD Shiley Eye Institute, Jacobs Retina Center","city":"La Jolla","state":"California","zip":"92093-0946","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Loma Linda University Eye Institute","city":"Loma Linda","state":"California","zip":"92354","country":"United States","geoPoint":{"lat":34.04835,"lon":-117.26115}},{"facility":"University of California San Francisco - Ophthalmology","city":"San Francisco","state":"California","zip":"94158","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"New York University School of Medicine - Oncology","city":"New York","state":"New York","zip":"10016","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Icahn School of Medicine at Mount Sinai","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"University Hospitals Cleveland Medical Center","city":"Cleveland","state":"Ohio","zip":"44106","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Lifespan - Women & Infants Hospital of RI","city":"Providence","state":"Rhode Island","zip":"02905","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"The Children's Hospital of San Antonio","city":"San Antonio","state":"Texas","zip":"78240","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"West Virginia University","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Acibadem City Clinic Multiprofile Hospital for Active Treatment","city":"Sofia","zip":"1407","country":"Bulgaria","geoPoint":{"lat":42.69751,"lon":23.32415}},{"facility":"Specialized Hospital for Active Treatment of Eye Diseases - Varna","city":"Varna","zip":"9002","country":"Bulgaria","geoPoint":{"lat":43.21912,"lon":27.91024}},{"facility":"Clinica Universitaria Bolivariana","city":"Medellín","state":"Antioquia","zip":"050034","country":"Colombia","geoPoint":{"lat":6.245,"lon":-75.57151}},{"facility":"Fundacion Oftalmologica de Santander Foscal","city":"Floridablanca","state":"Santander Department","zip":"681004","country":"Colombia","geoPoint":{"lat":7.06222,"lon":-73.08644}},{"facility":"SC Centrul Medical Unirea SRL","city":"Iași","zip":"700023","country":"Romania","geoPoint":{"lat":47.16667,"lon":27.6}},{"facility":"V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children - ophtalmology","city":"Moscow","state":"Moscow","zip":"119620","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"St. Petersburg State Pediatric Medical University - ophtalmology","city":"Saint Petersburg","zip":"194100","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Soon Chun Hyang University Cheonan Hospital","city":"Cheonan","state":"Chungcheongnam-do","zip":"31151","country":"South Korea","geoPoint":{"lat":36.8065,"lon":127.1522}},{"facility":"Chung-Ho Memorial Hospital","city":"Kaohsiung City","zip":"80756","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Chulalongkorn University","city":"Bangkok","state":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Prince of Songkla University - Ophthalmology","city":"Hat Yai","state":"Changwat Songkhla","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Phramongkutklao Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Queen Sirikit National Institute Of Child Health - Pediatrics","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Chiang Mai University","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Srinagarind Hospital - Ophthalmology","city":"Khon Kaen","zip":"4002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}},{"facility":"SBU Adana Sehir Training and Research Hospital","city":"Adana","zip":"4522","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe University Medical Faculty","city":"Ankara","zip":"06230","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Gazi University Medical Faculty Hospital","city":"Ankara","zip":"06560","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Eskisehir Osmangazi University Medical Faculty Hospital","city":"Eskişehir","zip":"26480","country":"Turkey (Türkiye)","geoPoint":{"lat":39.77667,"lon":30.52056}},{"facility":"Children's Hospital 1 - Ophthalmology Unit","city":"Ho Chi Minh City","state":"Thanh Pho","zip":"70000","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}},{"facility":"Hue Central Hospital","city":"Huế","state":"Thừa Thiên Huế Province","zip":"530000","country":"Vietnam","geoPoint":{"lat":16.4619,"lon":107.59546}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR","ANALYTIC_CODE"],"timeFrame":"When Regeneron has:\n\n* received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development\n* made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)\n* the legal authority to share the data, and\n* ensured the ability to protect participant privacy","accessCriteria":"Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf","url":"https://vivli.org/"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D012178","term":"Retinopathy of Prematurity"}],"ancestors":[{"id":"D012164","term":"Retinal Diseases"},{"id":"D005128","term":"Eye Diseases"},{"id":"D007235","term":"Infant, Premature, Diseases"},{"id":"D007232","term":"Infant, Newborn, Diseases"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"}]}},"hasResults":false}